RXRX News and Press, Recursion Pharmaceuticals Inc. From 02/25/26

2026-02-25 12:48:35 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript Recursion Pharmaceuticals: Stock Unres...

2026-02-25 11:42:41 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates Recursion Pharmaceuticals, Inc. (RXRX) Prese...

2026-02-25 06:32:25 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates Recursion Pharmaceuticals, Inc. (RXRX) Prese...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing with defined milestones Achieved fifth program milestone ...

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

2026-02-24 10:11:20 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates Recursion Pharmaceuticals, Inc. (RXRX) Prese...

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 ...

2026-02-23 07:46:06 ET More on ARK Invest Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2025 Update AI Can't Sustain This Rate Of Return ARKG: Cathie Wood's Biotech Product Is In Rally Mode ETF investors cheer as Deere & Company surges 13% after ea...

Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, F...

2026-02-18 05:20:31 ET Read the full article on Seeking Alpha For further details see: Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes